spx-101

Small moleculeexperimental

Clinical trial activity

3 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started May 31, 2017 (NCT03056989)

Timeline

2010s

Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Jan 1, 2017
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Amiloride-sensitive sodium channel alpha-subunitINHIBITOR
SCNN1A inhibitor
- Amiloride-sensitive sodium channel subunit alpha (SCNN1A) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@@H](C)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C)C(=O)N[C@H](C)C(N)=O)[C@@H](C)O

Mol. weight: 1179.38 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL6068525 ↗

Also known as

spx-101

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05231733	Phase 1	Apr 1, 2022	—
NCT03229252	Phase 2	Aug 1, 2017	Spyryx Biosciences, Inc.
NCT03056989	Phase 1	May 31, 2017	Spyryx Biosciences, Inc., University of Toronto

Showing 3 of 3 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Spyryx Biosciences, Inc.	For profit	2	2	2	2017
University of Toronto	Academic/Hospital	1	0	1	2017

2 organizations

Page 1 / 1